Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial.

Janes HE, Cohen KW, Frahm N, De Rosa SC, Sanchez B, Hural J, Magaret CA, Karuna S, Bentley C, Gottardo R, Finak G, Grove D, Shen M, Graham BS, Koup RA, Mulligan MJ, Koblin B, Buchbinder SP, Keefer MC, Adams E, Anude C, Corey L, Sobieszczyk M, Hammer SM, Gilbert PB, McElrath MJ.

J Infect Dis. 2017 May 1;215(9):1376-1385. doi: 10.1093/infdis/jix086.

2.

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults.

Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, DeZure A, Lynch RM, Gordon I, Plummer S, Hendel CS, Pegu A, Conan-Cibotti M, Sitar S, Bailer RT, Narpala S, McDermott A, Louder M, O'Dell S, Mohan S, Pandey JP, Schwartz RM, Hu Z, Koup RA, Capparelli E, Mascola JR, Graham BS; VRC 602 Study Team.

Clin Exp Immunol. 2015 Dec;182(3):289-301. doi: 10.1111/cei.12692. Epub 2015 Sep 24.

3.

Testing the waters: Ethical considerations for including PrEP in a phase IIb HIV vaccine efficacy trial.

Dawson L, Garner S, Anude C, Ndebele P, Karuna S, Holt R, Broder G, Handibode J, Hammer SM, Sobieszczyk ME; NIAID HIV Vaccine Trials Network.

Clin Trials. 2015 Aug;12(4):394-402. doi: 10.1177/1740774515579165. Epub 2015 Apr 7.

4.

Ethical considerations in HIV prevention and vaccine research in resource-limited settings.

Garner SA, Anude CJ, Adams E, Dawson L.

J Acquir Immune Defic Syndr. 2014 Sep 1;67(1):77-83. doi: 10.1097/QAI.0000000000000248.

PMID:
25117930
5.

Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine.

Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, Koblin BA, Buchbinder SP, Keefer MC, Tomaras GD, Frahm N, Hural J, Anude C, Graham BS, Enama ME, Adams E, DeJesus E, Novak RM, Frank I, Bentley C, Ramirez S, Fu R, Koup RA, Mascola JR, Nabel GJ, Montefiori DC, Kublin J, McElrath MJ, Corey L, Gilbert PB; HVTN 505 Study Team.

N Engl J Med. 2013 Nov 28;369(22):2083-92. doi: 10.1056/NEJMoa1310566. Epub 2013 Oct 7.

6.

Immuno-virologic outcomes and immuno-virologic discordance among adults alive and on anti-retroviral therapy at 12 months in Nigeria.

Anude CJ, Eze E, Onyegbutulem HC, Charurat M, Etiebet MA, Ajayi S, Dakum P, Akinwande O, Beyrer C, Abimiku A, Blattner W.

BMC Infect Dis. 2013 Mar 1;13:113. doi: 10.1186/1471-2334-13-113.

7.

Current status and future prospects of epidemiology and public health training and research in the WHO African region.

Nachega JB, Uthman OA, Ho YS, Lo M, Anude C, Kayembe P, Wabwire-Mangen F, Gomo E, Sow PS, Obike U, Kusiaku T, Mills EJ, Mayosi BM, Ijsselmuiden C.

Int J Epidemiol. 2012 Dec;41(6):1829-46. doi: 10.1093/ije/dys189.

8.

Children who acquire HIV infection perinatally are at higher risk of early death than those acquiring infection through breastmilk: a meta-analysis.

Becquet R, Marston M, Dabis F, Moulton LH, Gray G, Coovadia HM, Essex M, Ekouevi DK, Jackson D, Coutsoudis A, Kilewo C, Leroy V, Wiktor SZ, Nduati R, Msellati P, Zaba B, Ghys PD, Newell ML; UNAIDS Child Survival Group.

PLoS One. 2012;7(2):e28510. doi: 10.1371/journal.pone.0028510. Epub 2012 Feb 23.

9.

Standardizing surveillance of pneumococcal disease.

Knoll MD, Moïsi JC, Muhib FB, Wonodi CB, Lee EH, Grant L, Gilani Z, Anude CJ, O'Brien KL, Cherian T, Levine OS; PneumoADIP-Sponsored Surveillance Investigators.

Clin Infect Dis. 2009 Mar 1;48 Suppl 2:S37-48. doi: 10.1086/596480.

PMID:
19191618

Supplemental Content

Loading ...
Support Center